GE HealthCare Phase 2 results support advancing mangaciclanol MRI agent into Phase 3
FROM THE WIRE · FINANCE.YAHOO.COM
Key milestone in GE HealthCare's adaptive Phase 2/3 LUMINA clinical trial, with Phase 2 results meeting primary endpoint, showing mangaciclanol and market-leading gadolinium-based agent, gadobutrol, have similar overall diagnostic preference Mangaciclanol was well tolerated in…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA meaningful clinical milestone for GE HealthCare in the MRI contrast agent market.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Phase 2 results met the primary endpoint in the LUMINA trial.
- 02Mangaciclanol showed no safety concerns in Phase 2.
- 03The agent received FDA Fast Track designation.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
GE HealthCare Technologies Inc.83.66 USDAwaiting tradestoday +2.22%Positive GE HEALTHCARE TECH.INC.74.34 EURMarket closedtoday -1.95%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets